Lessons from the hearts of survivors of childhood cancer

Lynda M. Vrooman, Steven E Lipshultz, Stephen E. Sallan

Research output: Contribution to journalArticle

Abstract

With growing numbers of childhood cancer survivors, it becomes increasingly important to understand the long-term toxicities associated with cure from malignancy. Many survivors were exposed to cardiotoxic chemotherapeutic agents at young ages. Indeed, cardiotoxicity is a leading cause of treatment-related morbidity and mortality in survivors of childhood cancer, and anthracycline exposure is a leading cause of these late cardiac effects. Nonetheless, anthracyclines remain critical agents in treating many pediatric cancers. Strategies to prevent anthracycline-associated cardiotoxicity include limiting lifetime cumulative anthracycline doses and adding cardioprotectant agents, such as dexrazoxane, to anthracycline-based regimens. However, attempts to reduce the cardiotoxicity of anthracyclines must also consider their effect on anti-cancer efficacy as well as new potential toxicities. In survivors of childhood acute lymphoblastic leukemia, the data suggest that including dexrazoxane in anthracycline-based regimens can prevent heart damage, does not reduce anti-leukemic efficacy, and can be safely administered. The controversies associated with dexrazoxane exemplify the challenges of changing therapy in cancers with a relatively good chance of event-free survival in efforts to prevent long-term sequelae. Studies of very-long-term survivor cohorts will continue to inform current practices. Continued efforts are needed to minimize cardiotoxic exposures during cancer treatment, to deliver safe and effective cardioprotectant measures when cardiotoxic agents cannot be avoided, to identify patients at greatest risk of serious cardiac toxicity, and to educate providers in the optimal care of survivors.

Original languageEnglish (US)
Pages (from-to)51-55
Number of pages5
JournalProgress in Pediatric Cardiology
Volume36
Issue number1-2
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Anthracyclines
Survivors
Dexrazoxane
Cardiotoxins
Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Therapeutics
Pediatrics
Morbidity
Mortality
Cardiotoxicity

Keywords

  • Anthracycline
  • Cardiotoxicity
  • Childhood cancer survivor
  • Dexrazoxane
  • Late effects

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Lessons from the hearts of survivors of childhood cancer. / Vrooman, Lynda M.; Lipshultz, Steven E; Sallan, Stephen E.

In: Progress in Pediatric Cardiology, Vol. 36, No. 1-2, 2014, p. 51-55.

Research output: Contribution to journalArticle

Vrooman, Lynda M. ; Lipshultz, Steven E ; Sallan, Stephen E. / Lessons from the hearts of survivors of childhood cancer. In: Progress in Pediatric Cardiology. 2014 ; Vol. 36, No. 1-2. pp. 51-55.
@article{b7ccb857a95843699b11d21dbb42253b,
title = "Lessons from the hearts of survivors of childhood cancer",
abstract = "With growing numbers of childhood cancer survivors, it becomes increasingly important to understand the long-term toxicities associated with cure from malignancy. Many survivors were exposed to cardiotoxic chemotherapeutic agents at young ages. Indeed, cardiotoxicity is a leading cause of treatment-related morbidity and mortality in survivors of childhood cancer, and anthracycline exposure is a leading cause of these late cardiac effects. Nonetheless, anthracyclines remain critical agents in treating many pediatric cancers. Strategies to prevent anthracycline-associated cardiotoxicity include limiting lifetime cumulative anthracycline doses and adding cardioprotectant agents, such as dexrazoxane, to anthracycline-based regimens. However, attempts to reduce the cardiotoxicity of anthracyclines must also consider their effect on anti-cancer efficacy as well as new potential toxicities. In survivors of childhood acute lymphoblastic leukemia, the data suggest that including dexrazoxane in anthracycline-based regimens can prevent heart damage, does not reduce anti-leukemic efficacy, and can be safely administered. The controversies associated with dexrazoxane exemplify the challenges of changing therapy in cancers with a relatively good chance of event-free survival in efforts to prevent long-term sequelae. Studies of very-long-term survivor cohorts will continue to inform current practices. Continued efforts are needed to minimize cardiotoxic exposures during cancer treatment, to deliver safe and effective cardioprotectant measures when cardiotoxic agents cannot be avoided, to identify patients at greatest risk of serious cardiac toxicity, and to educate providers in the optimal care of survivors.",
keywords = "Anthracycline, Cardiotoxicity, Childhood cancer survivor, Dexrazoxane, Late effects",
author = "Vrooman, {Lynda M.} and Lipshultz, {Steven E} and Sallan, {Stephen E.}",
year = "2014",
doi = "10.1016/j.ppedcard.2014.09.008",
language = "English (US)",
volume = "36",
pages = "51--55",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Lessons from the hearts of survivors of childhood cancer

AU - Vrooman, Lynda M.

AU - Lipshultz, Steven E

AU - Sallan, Stephen E.

PY - 2014

Y1 - 2014

N2 - With growing numbers of childhood cancer survivors, it becomes increasingly important to understand the long-term toxicities associated with cure from malignancy. Many survivors were exposed to cardiotoxic chemotherapeutic agents at young ages. Indeed, cardiotoxicity is a leading cause of treatment-related morbidity and mortality in survivors of childhood cancer, and anthracycline exposure is a leading cause of these late cardiac effects. Nonetheless, anthracyclines remain critical agents in treating many pediatric cancers. Strategies to prevent anthracycline-associated cardiotoxicity include limiting lifetime cumulative anthracycline doses and adding cardioprotectant agents, such as dexrazoxane, to anthracycline-based regimens. However, attempts to reduce the cardiotoxicity of anthracyclines must also consider their effect on anti-cancer efficacy as well as new potential toxicities. In survivors of childhood acute lymphoblastic leukemia, the data suggest that including dexrazoxane in anthracycline-based regimens can prevent heart damage, does not reduce anti-leukemic efficacy, and can be safely administered. The controversies associated with dexrazoxane exemplify the challenges of changing therapy in cancers with a relatively good chance of event-free survival in efforts to prevent long-term sequelae. Studies of very-long-term survivor cohorts will continue to inform current practices. Continued efforts are needed to minimize cardiotoxic exposures during cancer treatment, to deliver safe and effective cardioprotectant measures when cardiotoxic agents cannot be avoided, to identify patients at greatest risk of serious cardiac toxicity, and to educate providers in the optimal care of survivors.

AB - With growing numbers of childhood cancer survivors, it becomes increasingly important to understand the long-term toxicities associated with cure from malignancy. Many survivors were exposed to cardiotoxic chemotherapeutic agents at young ages. Indeed, cardiotoxicity is a leading cause of treatment-related morbidity and mortality in survivors of childhood cancer, and anthracycline exposure is a leading cause of these late cardiac effects. Nonetheless, anthracyclines remain critical agents in treating many pediatric cancers. Strategies to prevent anthracycline-associated cardiotoxicity include limiting lifetime cumulative anthracycline doses and adding cardioprotectant agents, such as dexrazoxane, to anthracycline-based regimens. However, attempts to reduce the cardiotoxicity of anthracyclines must also consider their effect on anti-cancer efficacy as well as new potential toxicities. In survivors of childhood acute lymphoblastic leukemia, the data suggest that including dexrazoxane in anthracycline-based regimens can prevent heart damage, does not reduce anti-leukemic efficacy, and can be safely administered. The controversies associated with dexrazoxane exemplify the challenges of changing therapy in cancers with a relatively good chance of event-free survival in efforts to prevent long-term sequelae. Studies of very-long-term survivor cohorts will continue to inform current practices. Continued efforts are needed to minimize cardiotoxic exposures during cancer treatment, to deliver safe and effective cardioprotectant measures when cardiotoxic agents cannot be avoided, to identify patients at greatest risk of serious cardiac toxicity, and to educate providers in the optimal care of survivors.

KW - Anthracycline

KW - Cardiotoxicity

KW - Childhood cancer survivor

KW - Dexrazoxane

KW - Late effects

UR - http://www.scopus.com/inward/record.url?scp=84925967622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925967622&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2014.09.008

DO - 10.1016/j.ppedcard.2014.09.008

M3 - Article

AN - SCOPUS:84925967622

VL - 36

SP - 51

EP - 55

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

IS - 1-2

ER -